Research Impact

h-index

N/A

Research impact score

Publications

Total publications

Trial Results

Published trial results

Citations

Total citations

Drug Portfolio

MIXED(3)

DRUG(1)

Tablets

2 trials

phase_3

hellenic-institute-for-the-study-of-sepsis

Normal saline 0.9% or 5% dextrose water

1 trial

phase_2

hellenic-institute-for-the-study-of-sepsis

Bezlotoxumab

1 trial

phase_2

hellenic-institute-for-the-study-of-sepsis

3 unique interventions2 categories

Analytics

Trial Phases

Phase 21

Phase 32

Trial Status

Completed2

Recruiting1

Role Distribution

Other Roles3

Activity Timeline

Clinical Trials (3)

NCT06294600Phase 3Recruiting

Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)

Community-acquired Pneumonia

StudychairStart date: 2024-02-12

NCT05304715Phase 2Completed

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection

Clostridioides Difficile InfectionClostridioides Difficile Infection RecurrenceMortality+2 more

StudychairStart date: 2022-04-13

NCT04724044Phase 3Completed

Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia

BiomarkersCommunity-acquired PneumoniaInflammatory Response+3 more

StudychairStart date: 2021-01-25

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Community-Acquired Pneumonia2 Mortality2 Biomarkers1 Clostridium difficile Infections1 Clostridioides Difficile Infection Recurrence1 Inflammatory Response1 Organ Dysfunction Syndrome1 Sepsis1

Affiliations

Hellenic Sepsis Study Group

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Seetha Shankaran, MD

Wayne State University

49 trials

Shared therapeutic areas:

Sepsis

Similarity Score3%

Olivier Beauchet, MD

Jewish General Hospital

19 trials

Shared therapeutic areas:

Mortality

Similarity Score3%

Dale L. Phelps, MD

University of Rochester

10 trials

Shared therapeutic areas:

Sepsis

Similarity Score3%

Abhik Das, PhD

RTI International

31 trials

Shared therapeutic areas:

Sepsis

Similarity Score3%

Michele C. Walsh, MD MS

Case Western Reserve University, Rainbow Babies and Children's Hospital

11 trials

Shared therapeutic areas:

Sepsis

Similarity Score3%

Dong-Xin Wang, MD, PhD

Peking University First Hospital

74 trials

Shared therapeutic areas:

Mortality

Similarity Score3%

Sabine Hazan, MD

ProgenaBiome

41 trials

Shared therapeutic areas:

Clostridium difficile Infections

Similarity Score3%

Neil N. Finer, MD

University of California, San Diego

11 trials

Shared therapeutic areas:

Sepsis

Similarity Score3%

Edward F. Donovan, MD

Children's Hospital Medical Center, Cincinnati

21 trials

Shared therapeutic areas:

Sepsis

Similarity Score3%

Jon E. Tyson, MD MPH

University of Texas

6 trials

Shared therapeutic areas:

Sepsis

Similarity Score3%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT06294600Phase 3StudyChair

Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)

Community-acquired Pneumonia

Recruiting

NCT05304715Phase 2StudyChair

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection

Clostridioides Difficile InfectionClostridioides Difficile Infection RecurrenceMortality+2 more

Completed

NCT04724044Phase 3StudyChair

Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia

BiomarkersCommunity-acquired PneumoniaInflammatory Response+3 more

Completed

All 3 trials loaded